Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Actinium Pharmaceuticals's EV-to-OCF or its related term are showing as below:
ATNM'
s EV-to-OCF Range Over the Past 10 Years
Min: -231.25 Med: 0.04 Max: 28.28
Current: -0.39
During the past 13 years, the highest EV-to-OCF of Actinium Pharmaceuticals was 28.28. The lowest was -231.25. And the median was 0.04.
ATNM's EV-to-OCF is ranked worse than 70.89% of 1405
companies
in the Biotechnology industry
Industry Median: -3.4
vs ATNM: -0.39
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Actinium Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Actinium Pharmaceuticals's share price for today is $1.40.
Actinium Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.360.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Actinium Pharmaceuticals EV-to-OCF Related Terms
Actinium Pharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Actinium Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actinium Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Actinium Pharmaceuticals's EV-to-OCF falls into.
Actinium Pharmaceuticals's current Enterprise Value is $8.89 Mil.
Actinium Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actinium Pharmaceuticals (ATNM) has a EV-to-OCF of -0.39 as of Sep. 11, 2026. According to the industry distribution chart, Actinium Pharmaceuticals ranks #996 out of 1405 companies in the Biotechnology industry, placing it in the top 70.9%.
Is Actinium Pharmaceuticals' EV-to-OCF too high?
Actinium Pharmaceuticals' current EV-to-OCF is -0.39. Based on the distribution chart, Actinium Pharmaceuticals ranks #996 out of 1405 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Actinium Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Actinium Pharmaceuticals' EV-to-OCF compare to NNVC and IGC?
According to the Biotechnology industry distribution chart, Actinium Pharmaceuticals ranks #996 out of 1405 companies for EV-to-OCF. This places Actinium Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Actinium Pharmaceuticals's current EV-to-OCF is -0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinium Pharmaceuticals stock overvalued right now?
Actinium Pharmaceuticals (ATNM) has a current EV-to-OCF of -0.39. The current EV-to-OCF is -0.39. Actinium Pharmaceuticals' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Actinium Pharmaceuticals (ATNM), the current EV-to-OCF is -0.39 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
17GF Score
Get the complete analysis for ATNM
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATNM has been successfully added to your 
